Clinical Trial Update: A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating VAC85135, a neoantigen vaccine, given with ipilimumab for myeloproliferative neoplasms has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Neoplasms

Drugs mentioned

• VAC85135
• ipilimumab (ipilimumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Myeloproliferative Neoplasms | Phase 1 | Status: COMPLETED